12.12.23 -- Baxalta v. Genentech: The Latest Case In Patenting Functionally Claimed Antibodies

By transitioning to alternative solvents or leveraging process aids, the challenges associated with the use of these chemicals can be addressed, helping create a sustainable, greener footprint.

To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.

Here, we discuss the importance of understanding how critical process parameters can impact a product’s CQA and how a systematic approach with validated SPR assays can help in this respect.

The pharma industry is identifying new ways to improve sustainability. Discover how nanoparticle engineering technology can both empower sustainability goals and lead to better patient outcomes.

Learn from an expert about the process of assay development, qualification, and validation for potency assays and how we can support customers through this vital step.

Explore how the ADC landscape is being reshaped by new drug product capabilities that enable end-to-end development and manufacturing of cytotoxic bioconjugates.

Review the optimization of the manufacturing process of a pharmaceutical intermediate and discover how yield can be improved substantially via suitable reaction engineering.